Prado Yolanda, Tapia Pablo, Eltit Felipe, Reyes-Martínez Cristian, Feijóo Carmen G, Llancalahuen Felipe M, Riedel Claudia A, Cabello-Verrugio Claudio, Stehberg Jimmy, Simon Felipe
Laboratory of Integrative Physiopathology, Faculty of Life Science, Universidad Andres Bello, Santiago 8370186, Chile.
Millennium Institute on Immunology and Immunotherapy, Santiago 8331150, Chile.
Antioxidants (Basel). 2023 Feb 21;12(3):543. doi: 10.3390/antiox12030543.
Sepsis syndrome is a highly lethal uncontrolled response to an infection, which is characterized by sepsis-induced coagulopathy (SIC). High-density lipoprotein (HDL) exhibits antithrombotic activity, regulating coagulation in vascular endothelial cells. Sepsis induces the release of several proinflammatory molecules, including reactive oxygen species, which lead to an increase in oxidative stress in blood vessels. Thus, circulating lipoproteins, such as HDL, are oxidized to oxHDL, which promotes hemostatic dysfunction, acquiring prothrombotic properties linked to the severity of organ failure in septic-shock patients (SSP). However, a rigorous and comprehensive investigation demonstrating that oxHDL is associated with a coagulopathy-associated deleterious outcome of SSP, has not been reported. Thus, we investigated the participation of plasma oxHDL in coagulopathy-associated sepsis pathogenesis and elucidated the underlying molecular mechanism. A prospective study was conducted on 42 patients admitted to intensive care units, (26 SSP and 16 non-SSP) and 39 healthy volunteers. We found that an increased plasma oxHDL level in SSP was associated with a prothrombotic phenotype, increased mortality and elevated risk of death, which predicts mortality in SSP. The underlying mechanism indicates that oxHDL triggers an endothelial protein expression reprogramming of coagulation factors and procoagulant adhesion proteins, to produce a prothrombotic environment, mainly mediated by the endothelial LOX-1 receptor. Our study demonstrates that an increased plasma oxHDL level is associated with coagulopathy in SSP through a mechanism involving the endothelial LOX-1 receptor and endothelial protein expression regulation. Therefore, the plasma oxHDL level plays a role in the molecular mechanism associated with increased mortality in SSP.
脓毒症综合征是一种对感染的高度致命性失控反应,其特征为脓毒症诱导的凝血病(SIC)。高密度脂蛋白(HDL)具有抗血栓形成活性,可调节血管内皮细胞中的凝血过程。脓毒症会诱导多种促炎分子的释放,包括活性氧,这会导致血管中的氧化应激增加。因此,循环脂蛋白,如HDL,会被氧化为氧化型HDL(oxHDL),从而促进止血功能障碍,获得与脓毒性休克患者(SSP)器官衰竭严重程度相关的促血栓形成特性。然而,尚未有严谨且全面的研究表明oxHDL与SSP凝血病相关的有害结局有关。因此,我们研究了血浆oxHDL在凝血病相关脓毒症发病机制中的作用,并阐明了潜在的分子机制。对42名入住重症监护病房的患者(26名SSP患者和16名非SSP患者)以及39名健康志愿者进行了一项前瞻性研究。我们发现,SSP患者血浆oxHDL水平升高与促血栓形成表型、死亡率增加以及死亡风险升高相关,这可预测SSP患者的死亡率。潜在机制表明,oxHDL触发凝血因子和促凝黏附蛋白的内皮蛋白表达重编程,以产生促血栓形成环境,主要由内皮LOX-1受体介导。我们的研究表明,血浆oxHDL水平升高通过涉及内皮LOX-1受体和内皮蛋白表达调节的机制与SSP凝血病相关。因此,血浆oxHDL水平在与SSP患者死亡率增加相关的分子机制中起作用。